|
|
8 August, 2005: IRVINE, Calif., Aug. 9 : Cardiac Science Inc, a leading manufacturer of life-saving
automatic public-access defibrillators (AEDs), has settled its patent infringement
lawsuit against Defibtech, L.L.C. in the District Court of Minnesota in April, 2003.
Cardiac Science announced it would get a cash payment of $925,000 as part of
the deal.
Cardiac Science's allegations of infringement by Defibtech of United States Patent
No.'s 5,579,919, 5,700,281 and 6,038,473 and all of Defibtech's assorted
counterclaims have been fully resolved. Other terms and conditions of the
settlement are not known.
"This settlement further demonstrates the strength of our patent portfolio and
serves as yet another example where Cardiac Science has prevailed when our
intellectual property assets were threatened by a competitor. We will continue to
be vigilant in the marketplace in defending our inventions. And as our track record
demonstrates, when necessary, we will not shy away from seeking remedy in court
in order to dissuade our competitors, irrespective of their size or standing in the
marketplace, from inappropriately employing our patented AED features and
technology,” Cardiac Science's Chairman and CEO Raymond W. Cohen said in a PR
Newswire release.
The Cardiac Science CEO also said the company will aggressively pursue its patent
litigation against Philips which started in 2003.
Cardiac Science’s patent infringement lawsuit against Philips charges that Philips’
line of automated external defibrillators infringes 10 Cardiac Science United
States patents.
The Philips automated external defibrillators are promoted by Philips as including,
among other things, daily and weekly self-testing to determine presence and
functionality of pre-connected disposable defibrillation electrodes, features that
the Cardiac Science suit alleges are key competitive advantages of its Powerheart
line of AEDs and are covered under its patents.
Cardiac Science has over 70 US Patents relating to its external defibrillation
products and technology.
BY OUR PHARMA CORRESPONDENT
|
